2. Academic Validation
  3. AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma

AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma

  • PLoS One. 2022 Nov 3;17(11):e0276990. doi: 10.1371/journal.pone.0276990.
Chih-Hung Lin 1 2,  Han-Ni Chuang 3,  Tzu-Hung Hsiao 3 4 5,  V Bharath Kumar 6,  Chiung-Hung Hsu 7,  Chih-Yang Huang 7 8 9,  Li-Wen Lee 2,  Chien-Lin Mao 3,  Jiunn-Liang Ko 1 10,  Chung-Ping Hsu 2 11
Affiliations

Affiliations

  • 1 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • 2 Division of Thoracic Surgery, Department of Surgery, Taichung Veteran General Hospital, Taichung, Taiwan.
  • 3 Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
  • 4 Department of Public Health, Fu Jen Catholic University, New Taipei City, Taiwan.
  • 5 Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan.
  • 6 Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung, Taiwan.
  • 7 Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
  • 8 Center of General Education, Buddhist Tzu Chi Medical Foundation, Tzu Chi University of Science and Technology, Hualien, Taiwan.
  • 9 Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan.
  • 10 Department of Medical Oncology and Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • 11 Division of Thoracic Surgery, Department of Surgery, Buddhist Tzu Chi General Hospital, Hualien, Taiwan.
PMID: 36327302 DOI: 10.1371/journal.pone.0276990
Abstract

Despite multidisciplinary therapy, the prognosis is poor for esophageal squamous cell carcinoma (ESCC). In the locally advanced stage, neoadjuvant chemoradiotherapy (nCRT) followed by surgery could provide survival benefits to some patients. Here, we aimed to identify for tumor therapy response a biomarker based on RNA sequencing. We collected endoscopic biopsies of 32 ESCC patients, who were divided according to nCRT response, into two groups: the complete response group (n = 13) and the non-complete response group (n = 19). RNA-sequencing data showed that 464 genes were differentially expressed. Increased in non-complete response group, 4 genes increased expressions were AGR2 (anterior gradient 2), GADD45B (growth arrest and DNA damage inducible beta), PPP1R15A (protein Phosphatase 1 regulatory subunit 15A) and LRG1 (leucine rich alpha-2-glycoprotein 1). The areas under the curve (AUC) of the AGR2 gene was 0.671 according to read counts of RNA-seq and therapy response of nCRT. In vitro study showed that Apoptosis cell was significantly increased in the AGR2-knockdown TE-2 cell line treated with cisplatin and 5-Fluorouracil (5-FU), when compared with si-control. Results suggest that in ESCC, the AGR2 gene is a promising and predictive gene marker for the response to anti-tumor therapy.

Figures
Products